DoW Prostate Cancer, Data Science Award | HT942526PCRPDSA

FY26 Prostate Cancer Research Program (PCRP) Data Science Award (DSA) FAQs

1. What is the FY26 PCRP Data Science Award (DSA)?

The FY26 Prostate Cancer Research Program (PCRP) Data Science Award (DSA) is a Department of Defense grant opportunity that supports prostate cancer research driven by data-focused, quantitative approaches. It is aimed at projects that use computational, statistical, and analytical methods to generate meaningful insights from large and/or complex prostate cancer datasets.

2. What is the main purpose of this award?

The core purpose is to fund projects that either (a) develop new analytical approaches or (b) apply existing computational and statistical methods to extract useful knowledge from prostate cancer data that are high-volume, high-dimensional, or otherwise complex, with the goal of producing clinically or biologically meaningful insights.

3. What kinds of outcomes or impacts is the program looking for?

The emphasis is on converting complex data into insights that can improve understanding of disease mechanisms, refine risk prediction, support diagnosis, or guide treatment-related decision-making in prostate cancer research, with an eye toward eventual clinical impact.

4. What types of datasets are relevant for this opportunity?

Relevant datasets include large and/or complex prostate cancer datasets such as clinically annotated datasets (linked to patient characteristics, treatment details, and outcomes) and high-throughput molecular datasets (-omics), among others where modern computational approaches are necessary to extract meaning.

5. What research areas or methods does the award support?

Examples of supported areas and methods include analysis of clinically annotated datasets, -omics analysis (genomics, transcriptomics, proteomics, metabolomics, and other high-throughput profiles), artificial intelligence and machine learning, bioinformatics, computational biology, digital pathology (including quantitative analysis of whole-slide images), epidemiology, and medical imaging.

6. Does the award require that data science be central to the project?

Yes. The opportunity is designed for projects where sophisticated analytics are central rather than peripheral, and where data science methods are expected to produce new, defensible knowledge from complex prostate cancer data.

7. Do applicants need to have access to data at the time of application?

Competitive proposals are likely to demonstrate access to relevant data or provide a clear plan to generate, harmonize, or otherwise assemble the data needed, along with a robust analytical strategy.

8. Is alignment with program priorities required?

Yes. Every application must address at least one of the FY26 PCRP Overarching Challenges. Alignment is described as not optional and is likely to be evaluated as a key review criterion.

9. Are the FY26 PCRP Overarching Challenges listed here?

No. The specific list of FY26 PCRP Overarching Challenges is not included in the provided information. Applicants should consult the full announcement to identify the challenge(s) and map project aims and outputs accordingly.

10. What happens if a proposal does not clearly address an Overarching Challenge?

The opportunity indicates that even a strong data science proposal may be considered nonresponsive if it does not clearly map its aims and expected outputs to at least one FY26 PCRP Overarching Challenge.

11. Does the award allow multiple Principal Investigators (PIs)?

Yes. The mechanism explicitly allows multiple PIs, with a coordinated submission process led by an initiating PI.

12. What is the role of the initiating PI?

The initiating PI is responsible for submitting the pre-application. The initiating PI coordinates the overall submission for the collaborative project.

13. What is expected from partnering PIs at the full application stage?

At the full application stage, all PIs associated with the project are expected to submit their own full applications. Partnering PI submissions are described as abbreviated packages that cover their distinct portion of the overall project.

14. Does each PI need a defined scope of work?

Yes. The description implies each PI is accountable for a defined scope of work, expertise, and deliverables within an integrated research plan.

15. Is there a special risk for multi-PI submissions?

Yes. The opportunity warns that all associated applications for a given research project may be withdrawn if either the initiating PI application or any partnering PI application is rejected or administratively withdrawn.

16. What does the "linked fate" of multi-PI submissions mean in practice?

It means coordination and administrative compliance across all PI submissions is critical, because one weak, incomplete, rejected, or withdrawn component can jeopardize the entire collaborative submission.

17. Who administers this grant opportunity?

It is administered by the Defense Health Agency Contracting Activity (DHACA) under the Department of Defense.

18. What is the grant category and CFDA number?

This is a discretionary grant in the Science and Technology/Research and Development category, listed under CFDA 12.420.

19. What is the funding opportunity number and title?

The funding opportunity number is HT942526PCRPDSA, and the opportunity title is "DoW Prostate Cancer, Data Science Award."

20. What is the application deadline?

The original closing date listed is September 2, 2026.

21. How many awards are expected?

The posting indicates an expected four awards.

22. Is the maximum award amount (ceiling) provided here?

No. The award ceiling is not specified in the provided information, so applicants should consult the full announcement for budget limits and other financial details.

23. Are there applicant eligibility restrictions?

Eligibility is listed as unrestricted in the summary provided, meaning no applicant-type limits are stated in the provided extract.

24. What details should applicants expect to find only in the full announcement?

Based on the provided extract, applicants should consult the full announcement for the FY26 PCRP Overarching Challenges, budget limits (including any award ceiling), period of performance, allowable costs, and any cost-sharing or data-sharing expectations.

25. What makes a proposal more competitive based on the description provided?

Competitive proposals are likely to clearly align with at least one FY26 PCRP Overarching Challenge, demonstrate access to relevant data (or a credible plan to generate/harmonize it), present a robust computational/analytical strategy suitable for the data scale and complexity, and articulate a pathway to clinically or biologically meaningful prostate cancer insights.